Guardian Pharmacy Services, Inc. (GRDN) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Distribution
EV/EBITDA
23.88
↑+42% vs avg
5yr avg: 16.86
30Y Low16.9·High16.9
P/FCF
↓
33.27
↑+24% vs avg
5yr avg: 26.90
30Y Low23.6·High30.2
P/B Ratio
↑
12.32
↑+44% vs avg
5yr avg: 8.56
30Y Low8.4·High8.7
ROE
↓
26.8%
↓+120% vs avg
5yr avg: 12.1%
30Y Low-83%·High55%
Debt/EBITDA
↓
0.33
↓-63% vs avg
5yr avg: 0.90
30Y Low0.3·High1.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GRDN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Guardian Pharmacy Services, Inc. trades at 54.4x earnings, 41% above its 5-year average of 38.6x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 146%. On a free-cash-flow basis, the stock trades at 33.3x P/FCF, 24% above the 5-year average of 26.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.7B | $1.9B | $1.3B | — | — | — | — | — | — |
| Enterprise Value | $2.7B | $1.9B | $1.3B | — | — | — | — | — | — |
| P/E Ratio → | 54.37 | 38.58 | — | — | — | — | — | — | — |
| P/S Ratio | 1.85 | 1.31 | 1.02 | — | — | — | — | — | — |
| P/B Ratio | 12.32 | 8.74 | 8.38 | — | — | — | — | — | — |
| P/FCF | 33.27 | 23.60 | 30.20 | — | — | — | — | — | — |
| P/OCF | 26.78 | 18.99 | 21.67 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GRDN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Guardian Pharmacy Services, Inc.'s enterprise value stands at 23.9x EBITDA, 42% above its 5-year average of 16.9x. The Healthcare sector median is 14.2x, placing the stock at a 68% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.30 | 1.05 | — | — | — | — | — | — |
| EV / EBITDA | 23.88 | 16.86 | — | — | — | — | — | — | — |
| EV / EBIT | 29.88 | 21.10 | — | — | — | — | — | — | — |
| EV / FCF | — | 23.25 | 30.99 | — | — | — | — | — | — |
GRDN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Guardian Pharmacy Services, Inc. earns an operating margin of 6.1%. Operating margins have expanded from 3.9% to 6.1% over the past 3 years, signaling improving operational efficiency. ROE of 26.8% indicates solid capital efficiency. ROIC of 35.8% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.5% | 19.5% | 19.9% | 19.9% | 20.4% | 20.4% | 20.0% | 20.5% | 20.5% |
| Operating Margin | 6.1% | 6.1% | -5.1% | 3.9% | 5.7% | 3.8% | 4.4% | 4.9% | 4.3% |
| Net Profit Margin | 3.4% | 3.4% | -7.1% | 2.3% | 3.9% | 2.1% | 2.7% | 3.1% | 2.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 26.8% | 26.8% | -83.2% | 35.2% | 54.8% | 27.1% | 42.1% | 45.4% | 21.6% |
| ROA | 13.4% | 13.4% | -29.5% | 9.1% | 14.4% | 7.2% | 9.6% | 11.5% | 8.1% |
| ROIC | 35.8% | 35.8% | -30.4% | 23.0% | 33.7% | 21.3% | 23.6% | 26.4% | — |
| ROCE | 41.5% | 41.5% | -40.6% | 29.5% | 38.7% | 23.6% | 27.0% | 30.6% | 22.3% |
GRDN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Guardian Pharmacy Services, Inc. carries a Debt/EBITDA ratio of 0.3x, which is very conservative (90% below the sector average of 3.2x). The company holds a net cash position — cash of $66M exceeds total debt of $37M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 133.7x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.25 | 1.16 | 0.83 | 1.03 | 0.88 | 2.06 | 0.64 |
| Debt / EBITDA | 0.33 | 0.33 | — | 1.17 | 0.92 | 1.18 | 1.19 | 1.14 | 1.12 |
| Net Debt / Equity | — | -0.13 | 0.22 | 1.14 | 0.82 | 0.75 | 0.78 | 2.05 | 0.61 |
| Net Debt / EBITDA | -0.26 | -0.26 | — | 1.16 | 0.91 | 0.86 | 1.06 | 1.14 | 1.06 |
| Debt / FCF | — | -0.35 | 0.79 | 1.22 | 1.96 | 0.81 | 1.18 | 1.37 | 1.23 |
| Interest Coverage | 133.71 | 133.71 | -19.28 | 14.19 | 26.78 | 18.30 | 14.76 | 14.94 | 13.25 |
Net cash position: cash ($66M) exceeds total debt ($37M)
GRDN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.38x means Guardian Pharmacy Services, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.94x to 1.38x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | 1.38 | 1.05 | 0.94 | 1.07 | 1.00 | 1.09 | 1.00 | 1.24 |
| Quick Ratio | 1.11 | 1.11 | 0.77 | 0.67 | 0.70 | 0.71 | 0.72 | 0.66 | 0.82 |
| Cash Ratio | 0.41 | 0.41 | 0.03 | 0.01 | 0.01 | 0.13 | 0.07 | 0.00 | 0.03 |
| Asset Turnover | — | 3.51 | 3.83 | 3.86 | 3.55 | 3.36 | 3.38 | 3.55 | 3.30 |
| Inventory Turnover | 26.91 | 26.91 | 24.27 | 22.81 | 17.45 | 19.06 | 18.45 | 17.93 | 17.33 |
| Days Sales Outstanding | — | 25.60 | 28.87 | 26.96 | 27.24 | 25.46 | 22.70 | 28.34 | 28.97 |
GRDN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Guardian Pharmacy Services, Inc. returns 1.1% to shareholders annually primarily through share buybacks. The earnings yield of 1.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 2.8% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | 160.7% | 87.0% | 106.4% | 54.2% | 114.6% | 156.1% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.8% | 2.6% | — | — | — | — | — | — | — |
| FCF Yield | 3.0% | 4.2% | 3.3% | — | — | — | — | — | — |
| Buyback Yield | 1.1% | 1.5% | 4.4% | — | — | — | — | — | — |
| Total Shareholder Yield | 1.1% | 1.5% | 7.2% | — | — | — | — | — | — |
| Shares Outstanding | — | $63M | $62M | $61M | $61M | $61M | $61M | $61M | $61M |
Peer Comparison
Compare GRDN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GRDNYou | $3B | 54.4 | 23.9 | 33.3 | 19.5% | 6.1% | 26.8% | 35.8% | 0.3 |
 OMCL | $2B | 881.5 | 21.2 | 20.4 | 42.5% | 0.4% | 0.2% | 0.3% | 2.4 |
 PINC | $2B | 128.5 | 21.3 | 7.3 | 73.4% | 0.1% | 1.2% | 0.0% | 2.4 |
 CVS | $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 CCRN | $426M | -4.5 | 24.0 | 10.6 | 18.7% | -0.3% | -25.6% | -0.9% | 0.2 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 VEEV | $25B | 28.2 | 19.7 | 18.0 | 75.5% | 28.7% | 13.9% | 12.9% | 0.1 |
 ENSG | $9B | 26.3 | 23.5 | 24.2 | 13.7% | 8.6% | 16.9% | 7.0% | 7.7 |
 SEM | $2B | 14.0 | 12.1 | 5.4 | 11.5% | 6.1% | 7.3% | 4.8% | 7.8 |
 ADUS | $2B | 18.1 | 12.2 | 16.9 | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GRDN — Frequently Asked Questions
Quick answers to the most common questions about buying GRDN stock.
What is Guardian Pharmacy Services, Inc.'s P/E ratio?
Guardian Pharmacy Services, Inc.'s current P/E ratio is 54.4x. The historical average is 38.6x. This places it at the 100th percentile of its historical range.
What is Guardian Pharmacy Services, Inc.'s EV/EBITDA?
Guardian Pharmacy Services, Inc.'s current EV/EBITDA is 23.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.9x.
What is Guardian Pharmacy Services, Inc.'s ROE?
Guardian Pharmacy Services, Inc.'s return on equity (ROE) is 26.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 21.2%.
Is GRDN stock overvalued?
Based on historical data, Guardian Pharmacy Services, Inc. is trading at a P/E of 54.4x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Guardian Pharmacy Services, Inc.'s profit margins?
Guardian Pharmacy Services, Inc. has 19.5% gross margin and 6.1% operating margin.
How much debt does Guardian Pharmacy Services, Inc. have?
Guardian Pharmacy Services, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.